Gone are the days where serendipitous water cooler chats take place. Here's how to promote engagement and socialization in the modern workplace.  Photo via Getty Images

Wordle, the trendy daily word game and latest viral sensation, has taken millions of people by storm as they look for ways to feel connected and stimulated during times of isolation. The speed with which the word game took hold and quickly became a daily obsession is an example of society’s desire to participate in a common activity and share their scores and stats.

As managers search for ways to re-engage in-person, remote and hybrid teams, they should take cues from societal trends, behaviors and habits that can be easily adapted for the workplace. A unique tool that can help promote team engagement and serve as the foundation for an ongoing program begins with six letters – Wordle.

Below are ways managers can use Wordle and other activities to promote a cohesive and engaged workforce.

Create a virtual water cooler

Most employers and employees agree that a critical void in the existing work environment is gatherings around the proverbial water cooler, which facilitates daily chats about current events, hobbies and interests, social interactions that build bonds and teams, and opportunities for welcome breaks in the workday to clear the mind.

Managers should create a virtual water cooler by designating time each day for 15 to 30-minute coffee talks, depending on group sizes and workloads, that include semi-structured activities and enable employees to have valuable face time via video conferencing. Managers can poll the team about the best times of the day to host coffee talks. They should explain that while attending the talks is highly encouraged, there might be days when urgent projects/deadlines take precedence. Soliciting volunteers to coordinate and lead activities on a rotating, monthly basis encourages employee participation, promotes leadership skills and enables relationship building. When employees take the lead, they can more easily identify common interests, establish relevant formats and find ways to keep the team engaged and connected.

Develop the format

Managers and volunteers should develop a format tailored to the needs of the team, which can be fluid, structured or a combination of both to provide an optimal coffee talk experience. For example, some teams might need to have unstructured catch-up time every other day with planned activities on the remainder of the days, while other teams might prefer consistent daily activities and/or themes.

One of the advantages of coffee talk programs is that planners can experiment and request input because the ultimate goal is having dedicated time for face-to-face interactions that support an engaged workforce. The format should be inviting and not something employees dread, feel pressure to prepare for, or think is a waste of time. Coffee talks should create buzz and serve as a time that employees look forward to, offering a chance to decompress and leave energized to resume daily tasks. They are also critical for remote workers because it might be the only time during the workday they interact with others. This helps them remain connected to the team, culture and company.

Identify activities

Coffee talks are an ideal setting to incorporate Wordle into the agenda. Teams can create an account to virtually play the game daily, working together to solve the day’s new five-letter word and/or playing several practice games to extend the action. Wordle facilitates team building and encourages even those who are more reserved to take part in the activity. Conversely, employees who play the game at home can share and compare scores/stats from the previous night for friendly competition. Teams can also challenge other groups within the company to a monthly Wordle contest, helping to connect more people and expand networks, which is a great way for new employees to meet others.

An additional theme for coffee talks that can promote employee engagement is discussing the outcomes of sporting events, potential matchups and future winners. For example, the national sporting events get people buzzing and March Madness brackets/games are right around the corner. For employees not into sports, it can expand their horizons and/or even foster new interests and hobbies. In addition, with the prevalence of binge-watching and the continuous introduction of new programming, employees can talk about the latest shows, speculate on cliff hangers and make co-workers aware of new programs.

There are numerous activities that can be incorporated into coffee talks and employees can always find something to talk about that brings them together. Managers who can funnel these interactions into informal coffee talks are leveraging existing resources to encourage employee engagement and filling a critical need to keep employees connected, no matter the environment.

------

Jill Chapman is a senior performance consultant with Insperity, a leading provider of human resources and business performance solutions.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Top stories: Houston's most-read health tech news of 2024

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance, and more. Be sure to click through to read the full story.

New report ranks Houston top market for life sciences

Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. Photo by Natalie Harms/InnovationMap

Thanks in large part to producing hundreds of college-trained professionals, Houston’s life sciences industry ranks among the top U.S. markets for talent in 2024.

In a report published by commercial real estate services company CBRE, Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. From 2017 to 2022, Houston notched a growth rate of 32.4 percent in this category.

In 2022, the University of Houston led the higher education pack in the region, graduating 746 people with a bachelor’s degree or above in biological or biomedical sciences, according to the report. Continue reading.

Houston innovator raises pre-seed funding for health care staffing platform

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission." Continue reading.

Houston regenerative medicine company to IPO, move toward more human trials

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.” Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

FDA greenlights Houston surgery robotics company's unique technology

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

Houston billionaire Tilman Fertitta nominated as ambassador to Italy

foreign affairs

Houston billionaire and Rockets owner Tilman Fertitta has been nominated to serve as the United States ambassador to Italy, according to U.S. President-elect Donald Trump.

On Saturday, Trump sent the following statement via Truth Social Post:

"I am pleased to announce that Tilman J. Fertitta has been nominated to serve as the United States Ambassador to Italy. Tilman is an accomplished businessman, who has founded and built one of our Country's premier entertainment and real estate companies, employing approximately 50,000 Americans. Tilman has a long history of giving back to the community through numerous philanthropic initiatives, which include children's charities, Law Enforcement, and the medical community. Additionally, Tilman is the longest serving Chairman of the Board of Regents for the University of Houston. He also owns the Houston Rockets Basketball Team. Congratulations to Tilman, and his remarkable family!"

Fertitta, 67, also is the chairman, CEO, and president of Landry's Inc. and the chairman of the University of Houston's board of regents.

"It is an honor to be nominated to serve my country as ambassador to Italy and I look forward to the process ahead. Italy is such an extraordinary country with its wonderful people, culture, and history and its strategic importance to The United States of America," Fertitta said.

---

Read the full story on CultureMap's news partner, ABC13.com.

Houston biotech biz to merge with public co., set local HQ

big deal

Houston-based Tvardi Therapeutics and Cara Therapeutics announced the companies have entered into a definitive merger agreement to combine in an all-stock transaction. Once completed, Houston will house the headquarters.

Tvardi is a clinical-stage biopharmaceutical company that focuses on the development of novel, oral, and small molecule therapies that target STAT3 to treat fibrosis-driven diseases. Tvardi will merge with a wholly owned subsidiary of Cara.

Once complete, the pre-merger Cara Therapeutics stockholders are expected to own approximately 17 percent of the combined company and pre-merger Tvardi Therapeutics investors are expected to own 83 percent of the combined company. Prior to adjustment from the issuance of the shares in the recently completed Tvardi financing and assuming Cara, which went public in 2014, has net cash at closing of between $22.9 million and $23.1 million with the percentage of the combined company that pre-merger Cara stockholders and pre-merger Tvardi stockholders will own upon the closing of the merger, which is subject to further adjustment if Cara’s net cash balance falls outside of the range.

“As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis, followed by the readout in our hepatocellular carcinoma program, this merger, the recently completed financing, and becoming a publicly traded company give us access to the critical funding required to further advance our promising pipeline programs that address significant unmet needs,” Imran Alibhai, CEO of Tvardi Therapeutics, says in a news release.

Also, Tvardi has completed an approximately $28 million private financing from a syndicate of new and existing institutional investors. With the cash from both companies at closing and the proceeds of this financing, the post-merger company plans to have cash to fund its operating expenses and capital expenditure requirements into the second half of 2026.

“I am grateful to the Cara Board, leadership team, and shareholders who share our vision of Tvardi that is well-positioned to introduce effective, new treatment options to patients suffering from serious, chronic, fibrosis-driven diseases,” Alibhai continues.

In 2021, Tvardi emerged from stealth and closed a $74 million series B funding round led by New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.